The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months. Data will be collected beginning 6 months before the participant started Tresiba® up to around 6 months after the participant started taking insulin degludec.

Inclusion Criteria:

• Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient
• Male or female age greater than or equal to 18 years at the time of insulin degludec initiation
• Type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients
• Switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with insulin degludec at the time of patient selection
• Previously treated with any basal insulin (± prandial insulin) for at least 6 months prior to switching to insulin degludec
• At least one documented medical visit in the first 6 months (closest value in 3 to 9 months window) after insulin degludec initiation
• Minimum available data at the time of insulin degludec initiation: age, type of diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site for at least 1 year, and an estimated glomerular filtration rate (eGFR) value in the last 12 ±6 months (full data period)

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having signed the Informed Consent in this study
• Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba

Patients with type 1 or type 2 diabetes mellitus whose basal insulin was switched to insulin degludec

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com